How Wegovy suppresses appetite: the facts behind the feeling

The biggest myth: Wegovy simply switches hunger off

The most common misconception is that semaglutide works like a tap you turn off, appetite gone, problem solved. That is not quite what happens. GLP-1, the hormone Wegovy mimics, is part of a complex signalling loop. It acts on receptors in the hypothalamus to reduce appetite-driving signals, and it slows gastric emptying so food sits in the stomach longer. If you are wondering whether Wegovy actually works as an appetite suppressant, the honest answer is that most people feel fuller faster and stay satisfied longer after meals, but hunger does not disappear entirely, and it does not vanish on day one.

In the STEP 1 trial (published in the New England Journal of Medicine and involving nearly 2,000 adults with obesity) participants on semaglutide 2.4mg lost an average of around 15% of their body weight over 68 weeks alongside lifestyle changes. That result reflects sustained appetite reduction over months, not an immediate off switch. Many participants described a gradual quietening of food preoccupation rather than a dramatic change in the first week or two.

The practical implication: if you expect to feel no hunger at all from the first pen, the early weeks can feel confusing. Appetite suppression typically deepens as the dose increases toward the 2.4mg maintenance level, and if appetite suppression seems absent or patchy, there are usually explainable reasons worth discussing with your prescriber.

Why appetite feels inconsistent (especially around dose changes

A question our prescribers hear regularly: "My appetite was well controlled last week, but this week I feel hungry again) has it stopped working?" Fluctuation is normal. GLP-1 receptor agonists produce their effects through a steady-state blood level that takes a few weeks to settle after each dose increase. The period immediately after moving up a dose can feel less settled, not more, as the body adjusts to a higher concentration.

Other factors interact with appetite suppression too. Hydration matters: mild dehydration can mimic hunger. Sleep quality affects ghrelin, a separate hunger hormone that Wegovy does not directly target. And stress-related eating (driven by cortisol rather than physical hunger) may continue regardless of GLP-1 activity. The NHS patient information for semaglutide notes that the most common side effects are gastrointestinal, particularly in the early weeks and around dose increases, which can itself affect how appetite feels day to day.

None of this means the medicine is not working. It means appetite suppression on Wegovy is a biological process, not a binary switch, and it interacts with the rest of your physiology. If the inconsistency concerns you, your prescriber is the right person to speak to, not a forum. For a broader sense of how reliably Wegovy suppresses appetite across different people, the clinical data provide a useful reference point.

What reduced appetite actually means for how you eat

Appetite suppression changes the quantity people want to eat. It does not automatically change the quality, or guarantee that what is eaten covers nutritional needs. This is where the practical challenge sits. When meals shrink significantly, protein becomes harder to hit in absolute grams. Fibre intake can fall. And because you feel less urgency around eating, it is easy to skip meals entirely, which can compound tiredness and muscle loss over time.

The question of what to eat on Wegovy deserves its own attention. The broad principle is the same as in clinical trials: a reduced-calorie diet alongside increased physical activity. In practice, prioritising protein at each meal (eggs, fish, chicken, legumes), maintaining fibre through vegetables and wholegrains, and drinking enough water through the day all support the treatment rather than competing with it.

The British Dietetic Association's food facts resource is a useful starting point for building balanced meals around a smaller appetite. A dietitian can take it further if your nutritional needs are more complex. Your prescriber can advise on when a referral makes sense.

Who can access Wegovy in the UK, and what the process looks like

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or raised cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber reviews the full clinical picture before treatment starts, BMI alone is not the whole assessment.

On the NHS, access is through specialist weight management services and involves waiting lists that are, in many areas, long. Private treatment through a regulated online pharmacy is the alternative for people who do not qualify under current NHS criteria or do not want to wait. If you are considering the cost of Wegovy in the UK, it is worth understanding what a legitimate private price should include: the consultation, the prescription, clinical oversight and ongoing support, not just the pen itself.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber. If approved, your treatment is dispatched the same day (for orders placed before midday, Monday to Friday) and arrives the next working day via DPD, tracked to your door in plain, unbranded packaging. No subscription, no auto-renewal. If you would like to understand more about Wegovy as a treatment before deciding, our treatment page covers the clinical picture in full. When you are ready, check your eligibility with a free consultation.